Merger Remedies Brazil 2026, CADE Expectations on Divestitures, Trustees and Fix‑it‑first

Merger remedies Brazil practice has moved to the centre of deal planning in 2026, as the Administrative Council for Economic Defense (CADE) sharpens its scrutiny of concentrations that raise competitive concerns. Deal teams pursuing transactions with a Brazilian nexus now treat remedies not as an afterthought but as a core determinant of closing certainty. With re‑energised enforcement and rising deal volumes, structural divestitures, fix‑it‑first offers and trustee mechanics increasingly define how conditional approvals are structured and delivered. This practitioner guide sets out what CADE expects, how remedies interact with transaction documentation, and the practical steps in‑house counsel and external advisers should take from pre‑signing through to full divestiture implementation.

Who this is for: in‑house counsel, corporate development, private equity deal teams and external counsel planning mergers in Brazil. This guide explains CADE’s remedies practice in 2026, how remedies affect closing certainty, and the practical drafting and negotiation steps that reduce clearance risk. For broader context, see our M&A lawyers Brazil, GLE country practice page.

Quick summary: what deal teams must know now

Before diving into detail, the essentials for anyone assessing merger remedies Brazil risk in 2026 can be distilled into a short list:

• Structural preference. CADE continues to favour clean structural divestitures over long‑running behavioural commitments where market concentration is significant.
• Fix‑it‑first is growing. Parties who identify a credible buyer and remedy package before or during review can materially improve timing and certainty.
• Trustee scrutiny is rising. Divestiture and monitoring trustees face closer oversight; selection, mandate and reporting are negotiated carefully.
• Timing and closing risk. Remedy negotiations can extend the review timetable, so conditions precedent and hold‑separate governance must be built into the transaction documents.
• Pre‑signing preparation matters. Early identification of remedy risk in due diligence shapes deal economics, break‑fee allocation and closing mechanics.

Deal team tip: treat remedy strategy as a workstream that begins before the transaction agreement is signed, not one triggered only after CADE raises concerns.

How CADE’s merger review works, a short primer

Brazilian merger control operates under Law No. 12.529 of 30 November 2011, which created the current structure of CADE and set out its powers to review concentrations and impose conditions. Understanding the procedural framework is essential to any discussion of merger remedies Brazil practice, because the point at which remedies are negotiated shapes both leverage and timing.

Brief timeline: notification to remedies

The lifecycle of a reviewable concentration typically follows a predictable path: notification of the transaction to CADE, an initial review by the General Superintendence (Superintendência-Geral), and either a fast‑track clearance for unproblematic deals or a more detailed examination where competitive concerns arise. Where the authority identifies potential harm, remedy negotiations begin, culminating in a decision, by the General Superintendence or, in more complex cases, by CADE’s Administrative Tribunal, that may approve the deal outright, block it, or approve it subject to conditions. If conditions include divestitures, the process continues into trustee appointment and divestiture implementation, which can run well beyond the formal clearance date.

Legal basis and procedural stages

Law No. 12.529/2011 provides the statutory foundation for merger control and for CADE’s authority to impose restrictions, obligations and conditions when approving a concentration. The framework distinguishes between transactions that qualify for a simplified, fast‑track review and those requiring ordinary examination. For deal teams, the critical takeaway is that Brazil operates a pre‑closing suspensory regime: reviewable transactions that meet the applicable notification thresholds must be notified and must not be consummated before clearance, which makes hold‑separate and interim governance measures central to any deal where remedies are anticipated. Conditional approvals are formalised through a merger control agreement, in Portuguese, an Acordo em Controle de Concentrações (ACC), which records the negotiated commitments and their enforcement terms.

What remedies does CADE require?

CADE draws on a spectrum of remedies to address competitive concerns, and the choice among them reflects the nature of the harm, the structure of the affected market, and the authority’s confidence in each measure’s effectiveness. When assessing merger remedies Brazil options, deal teams should understand the three broad categories the authority deploys.

Structural remedies

Structural remedies require the parties to divest assets, business units, brands, or entire operating divisions to a suitable independent purchaser. The appeal of structural remedies from CADE’s perspective is that they resolve the competitive concern permanently and require little ongoing supervision once implemented. A divestiture restores an independent competitor to the market, eliminating the need for the authority to police the merged entity’s conduct over time. For this reason, where a transaction significantly increases concentration in a well‑defined market, CADE tends to prefer a clean structural divestiture (remédio estrutural) over commitments that depend on future behaviour.

Behavioural remedies

Behavioural remedies (remédios comportamentais) constrain the conduct of the merged entity rather than altering its asset base. They can include obligations to grant access to essential infrastructure or inputs, to continue supplying customers on non‑discriminatory terms, to refrain from bundling, to limit the scope and duration of non‑compete undertakings, or to submit periodic compliance reports. Behavioural commitments are typically reserved for cases where a structural fix is disproportionate or impractical, for example, in vertical transactions where foreclosure risk can be addressed by supply or access guarantees. Their weakness is that they demand sustained monitoring, and their effectiveness depends on the merged party’s continued compliance.

Interim and hold‑separate measures

Because Brazil’s regime is suspensory, parties frequently need interim safeguards while review is pending or while a divestiture is being executed. Hold‑separate obligations require that the target or the business to be divested be maintained as a separate, viable and competitive concern, ring‑fenced from integration with the acquirer. These measures may be reinforced by escrow arrangements, performance bonds, or the appointment of a hold‑separate manager to preserve the value and independence of the assets. Hold‑separate governance is designed to prevent the loss of competitive vigour or the transfer of sensitive information before a remedy is fully implemented.

Red flags to watch:

• High post‑transaction market share in a concentrated market with limited alternative competitors.
• Significant barriers to entry that make behavioural access remedies difficult to police.
• Vertical relationships creating credible input or customer foreclosure concerns.
• Overlaps in markets where CADE has previously imposed divestitures.

Fix‑it‑first: mechanics, evidence and when CADE accepts it

The fix‑it‑first approach has become one of the most strategically important tools in the merger remedies Brazil toolkit for deal teams seeking speed and certainty. Rather than agreeing a remedy in principle and then searching for a buyer, the parties present CADE with a concrete, implemented or near‑implemented solution, typically an identified purchaser for the divested business, before or during the review.

What is fix‑it‑first?

A fix‑it‑first (fix‑it‑first brazil) remedy is one in which the merging parties resolve the competitive concern up front, often by entering a binding sale agreement with an approved buyer for the problematic assets before CADE finalises its decision. Instead of a promise to divest within a future window, the authority is asked to assess a fully specified transaction: a defined perimeter, an identified and vetted purchaser, and a credible commercial rationale for the buyer’s ability to compete effectively.

When CADE prefers fix‑it‑first over an open divestiture

CADE is more inclined to accept a fix‑it‑first solution when it removes execution and buyer‑suitability risk that would otherwise attach to a deferred divestiture. An open divestiture, where the parties commit to sell within a set period to a purchaser to be found later, carries the risk that no suitable buyer emerges, that the assets deteriorate, or that the eventual purchaser lacks the incentive and capability to replace the lost competition. By contrast, a fix‑it‑first offer lets the authority evaluate the actual buyer and the actual perimeter, reducing uncertainty and often shortening the path to clearance.

Evidence CADE expects

To secure acceptance of a fix‑it‑first package, parties should be prepared to demonstrate:

• Buyer suitability. Evidence that the purchaser is independent of the merged entity, financially capable, and has the commercial incentive and capacity to operate the divested business as a viable competitor.
• Perimeter completeness. That the divested package includes all the assets, contracts, personnel and intangibles necessary to compete, not a stripped‑down shell.
• Implementation timelines. A credible, documented plan and schedule showing how the divestiture will be executed and when.
• Independent verification. Where relevant, reports from independent auditors, valuers or a proposed monitoring trustee confirming the viability of the arrangement.

Deal team tip: begin quiet buyer‑sounding early where a divestiture looks likely; a credible fix‑it‑first candidate identified before notification can be the difference between a smooth clearance and a prolonged remedies negotiation.

Structural vs behavioural remedies in merger remedies Brazil practice

Choosing between structural and behavioural measures is one of the most consequential decisions in any merger remedies Brazil negotiation. The two approaches differ across permanence, monitoring burden, implementation speed and market effect. The following comparison provides a decision framework for deal teams.

Decision factors for the parties

When weighing which route to propose, deal teams should consider: the degree of industry concentration and the number of remaining competitors; the height of entry barriers, which determines whether behavioural access remedies can realistically discipline the market; the practicality and cost of ongoing monitoring; and the strategic value of the assets that a structural remedy would remove. In vertically related transactions, behavioural commitments addressing foreclosure may be viable; in horizontal overlaps within concentrated markets, a divestiture is usually the more credible offer. Framing the proposal in line with CADE’s evident preference for effective, low‑supervision outcomes improves the odds of a swift conditional approval.

Divestiture implementation: trustees, hold‑separate and enforcement mechanics

Securing a conditional approval is only the beginning; the operational challenge lies in delivering the remedy. This is where the divestiture trustee brazil framework, hold‑separate governance and enforcement mechanics determine whether a remedy actually works.

Trustee appointment, who and how

Two distinct roles typically feature in divestiture packages. A monitoring trustee oversees compliance with interim obligations, including hold‑separate measures, and reports to CADE on the parties’ conduct during the transition. A divestiture trustee may be empowered to conduct the sale of the assets, often with a mandate to sell to a suitable purchaser at no minimum price if the parties fail to complete the divestiture themselves within the agreed period. The trustee is expected to be independent of the parties, professionally qualified, and free of conflicts. Selection is generally proposed by the parties and subject to CADE’s approval, with the authority retaining the ability to reject an unsuitable candidate.

Key points to address in a trustee mandate include:

• Scope of authority. Precisely what the trustee may monitor, report on, or execute.
• Independence and conflicts. Confirmation that the trustee has no prior or current commercial relationship undermining impartiality.
• Access rights. Entitlement to information, personnel, premises and records necessary to perform the mandate.
• Reporting cadence. Frequency and content of reports to CADE.
• Divestiture powers. For a divestiture trustee, the ability to run a sale process, negotiate terms and complete a transaction if the parties default.
• Remuneration and cost allocation. How the trustee is paid and by whom, structured to preserve independence.

Trustee monitoring and reporting

Effective monitoring depends on clear, measurable indicators. Deal teams and CADE benefit from agreeing monitoring KPIs at the outset, for example, evidence that the ring‑fenced business retains its customer base, that separate management and information barriers are maintained, that no key employees are transferred out, and that the assets’ competitive viability is preserved. The monitoring trustee’s periodic reports give CADE ongoing visibility, and any material breach can trigger enforcement or acceleration of the divestiture trustee’s powers.

Hold‑separate governance, carve‑outs and access to people and IP

Hold‑separate (hold‑separate brazil) arrangements require careful design so that the business to be divested continues to operate as a genuine competitor pending sale. That means insulating it from the acquirer’s control, maintaining separate management with appropriate incentives, and preventing the flow of competitively sensitive information between the businesses. Carve‑outs must ensure that shared functions, IT systems, intellectual property licences, key personnel and supply arrangements, are allocated or replicated so the divested unit is viable on a standalone basis. Where the business depends on shared IP or seconded staff, transitional arrangements need to be documented to protect both the divested unit’s viability and the confidentiality that hold‑separate is meant to preserve.

Deal team tip: map shared functions and dependencies during due diligence. Identifying entanglements early makes it far easier to define a clean divestiture perimeter and to design hold‑separate carve‑outs that CADE will accept.

How remedy conditions affect M&A documentation and closing certainty

Remedies do not sit in isolation from the transaction agreement; they reshape conditions precedent, risk allocation and closing mechanics. Anticipating merger remedies Brazil outcomes at the drafting stage is what separates a resilient deal from one exposed to clearance failure.

Conditions precedent and covenants to close

Parties must decide how antitrust clearance conditions in Brazil are treated in the agreement. A common tension is between framing clearance, including acceptable remedies, as a pure condition precedent, and imposing a positive covenant obliging one or both parties to take specified steps to obtain clearance. A covenant‑to‑close (sometimes styled as a “hell or high water” or, more commonly, a limited best‑efforts obligation) determines who bears the burden of offering divestitures or behavioural commitments. Drafting should specify the extent of the obligation to accept remedies, any cap on the assets a party must divest, and the consequences if clearance is refused or only granted on unacceptable terms.

Escrow, reverse break fees and contingency divestiture clauses

Where remedy risk is material, the transaction agreement (the ACC merger agreement brazil context makes documentation especially important) should address the commercial fallout of remedy conditions. Reverse break fees can compensate a seller if the buyer walks away rather than accept required divestitures. Escrow arrangements may secure the performance of hold‑separate or divestiture obligations. Contingency divestiture clauses, pre‑agreed mechanics for identifying, ring‑fencing and selling assets should CADE demand it, reduce execution uncertainty and speed post‑clearance implementation. These provisions should dovetail with the trustee framework so that, if the parties default, the divestiture trustee can act without contractual ambiguity.

Interaction with foreign clearances

For multi‑jurisdictional deals, CADE’s remedies must be reconciled with conditions imposed by other authorities. Divergent perimeters or inconsistent behavioural commitments can create operational conflicts, so cross‑border deal teams should coordinate remedy design, buyer approval and implementation timelines across jurisdictions. International best practice on remedy design and monitoring, reflected in OECD guidance, supports alignment of trustee roles and divestiture standards to avoid duplicative or contradictory obligations.

Practical negotiation checklist and timeline for deal teams

A disciplined process improves both speed and outcomes. The following checklist maps the key steps for managing merger remedies Brazil risk from pre‑notification through to implementation.

Pre‑notification due diligence to identify remedy risk

• Map product and geographic overlaps and estimate post‑transaction market positions.
• Identify vertical relationships that could raise foreclosure concerns.
• Assess likely remedy exposure and define a defensible divestiture perimeter early.
• Sound out potential fix‑it‑first buyers discreetly where a divestiture is probable.

Negotiation timing and interim measures

• Prepare a remedy proposal and supporting economic analysis before CADE raises formal concerns.
• Design hold‑separate governance and interim measures to preserve asset viability during review.
• Decide whether to lead with a fix‑it‑first offer or an open divestiture based on buyer readiness.

Trustee selection and procurement

• Shortlist independent, conflict‑free trustee candidates with relevant sector experience.
• Draft mandate terms covering scope, access, reporting and divestiture powers.
• Agree monitoring KPIs and reporting cadence with CADE.
• Build a realistic procurement and implementation timeline into the transaction agreement.

Deal team tip: the timeline for remedies runs on two clocks, the clearance clock and the implementation clock. Plan for both, and make sure the transaction agreement’s long‑stop date accommodates a realistic divestiture period.

Recent CADE practice and what it signals for 2026 deals

Recent CADE practice reinforces several themes relevant to any merger remedies Brazil strategy in 2026. While each case turns on its facts, the direction of travel is broadly consistent:

• Continued structural emphasis. In concentrated horizontal markets, CADE has continued to prioritise divestitures that restore an independent competitor over behavioural fixes.
• Closer trustee oversight. The authority has paid increasing attention to trustee independence, mandate clarity and the robustness of monitoring reporting.
• Openness to fix‑it‑first where credible. Where parties present a suitable, vetted purchaser and a complete divestiture perimeter, CADE has shown willingness to accept fix‑it‑first solutions that reduce execution risk.
• Scrutiny of hold‑separate viability. Interim measures are examined for whether they genuinely preserve competitive vigour, not merely nominal separation.

For up‑to‑date decision texts and remedy orders, deal teams should consult CADE’s official decision database and the publication of orders in the Official Gazette (Diário Oficial da União).

Conclusions and next steps for deal teams

Merger remedies Brazil practice in 2026 rewards preparation. CADE’s evident preference for effective, low‑supervision structural solutions, its openness to well‑evidenced fix‑it‑first offers, and its closer scrutiny of trustee arrangements all point in one direction: remedy strategy should be embedded in the deal from the outset. Teams that identify remedy risk during due diligence, design credible divestiture perimeters, prepare hold‑separate governance and align transaction documentation with the eventual remedy will secure faster clearances and greater closing certainty. Those who treat remedies as a late‑stage afterthought face prolonged negotiations, execution risk and potential deal failure. The practical playbook is straightforward, anticipate, evidence, and document, and the payoff is a smoother path through Brazilian merger control.

For tailored guidance, explore our M&A resources and connect with the specialists at Global Law Experts.

Sources

1. Law No. 12.529, 30 November 2011 (Brazil), competition framework
2. Administrative Council for Economic Defense (CADE), official site
3. Diário Oficial da União (Official Gazette)
4. Ordem dos Advogados do Brasil (OAB)
5. OECD, Competition, merger control and remedies guidance
6. FGV Direito SP, competition law research